Vandetanib: a guide to its use in advanced medullary thyroid cancer.
Keating GM, Lyseng-Williamson KA, Frampton JE.
BioDrugs · review; journal article · DOI 10.1007/bf03261900 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för vandetanib. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
64 träffarVandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ.
Lancet Oncol · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/s1470-2045(12)70335-2Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG.
PLoS One · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0038231Vandetanib for the treatment of lung cancer.
Chu CT, Sada YH, Kim ES.
Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2012.694866Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.
Thornton K, Kim G, Maher VE, Chattopadhyay S, Tang S, Moon YJ, Song P, Marathe A, Balakrishnan S, Zhu H, Garnett C, Liu Q, Booth B, Gehrke B, Dorsam R, Verbois L, Ghosh D, Wilson W, Duan J, Sarker H, Miksinski SP, Skarupa L, Ibrahim A, Justice R, Murgo A, Pazdur R.
Clin Cancer Res · randomized controlled trial; journal article · DOI 10.1158/1078-0432.ccr-12-0411Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
Minocha M, Khurana V, Qin B, Pal D, Mitra AK.
Int J Pharm · research-article; journal article · DOI 10.1016/j.ijpharm.2012.05.028Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice.
Inoue K, Torimura T, Nakamura T, Iwamoto H, Masuda H, Abe M, Hashimoto O, Koga H, Ueno T, Yano H, Sata M.
Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-11-2041Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
Guérin O, Etienne-Grimaldi MC, Monteverde M, Sudaka A, Brunstein MC, Formento P, Lattanzio L, Maffi M, Tonissi F, Ortholan C, Pagès G, Fischel JL, Lo Nigro C, Merlano M, Milano G.
Urol Oncol · journal article · DOI 10.1016/j.urolonc.2012.03.003Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.
Almeida MQ, Hoff AO.
Curr Opin Oncol · review; journal article · DOI 10.1097/cco.0b013e328351c71aCombined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms.
Jo MY, Kim YG, Kim Y, Lee SJ, Kim MH, Joo KM, Kim HH, Nam DH.
Mol Med Rep · research support, non-u.s. gov't; journal article · DOI 10.3892/mmr.2012.868Role of vandetanib in the management of medullary thyroid cancer.
Brassard M, Rondeau G.
Biologics · review-article; journal article · DOI 10.2147/btt.s24220[The role of Src kinase inhibitor ZD6474 on multi-drug resistant K562/A02 cells].
Jia HY, Li J, Wang ZY, Zhou Q, Wu XM.
Zhonghua Xue Ye Xue Za Zhi · research support, u.s. gov't, non-p.h.s.; journal articleVandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, Chen YM, Emerson L, Langmuir P, Manegold C.
J Clin Oncol · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1200/jco.2011.36.1709Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma.
Klein JD, Christopoulos A, Ahn SM, Gooding WE, Grandis JR, Kim S.
Head Neck · research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/hed.21917Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.
Langenkamp E, Zwiers PJ, Moorlag HE, Leenders WP, St Croix B, Molema G.
Anticancer Drugs · research support, non-u.s. gov't; research-article; journal article · DOI 10.1097/cad.0b013e32834dc279Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.
Hsu C, Yang TS, Huo TI, Hsieh RK, Yu CW, Hwang WS, Hsieh TY, Huang WT, Chao Y, Meng R, Cheng AL.
J Hepatol · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.jhep.2011.12.013A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.
Robak P, Robak T.
Curr Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.2174/092986712803833371Photosensitivity reactions to vandetanib: redevelopment after sequential treatment with docetaxel.
Son YM, Roh JY, Cho EK, Lee JR.
Ann Dermatol · journal article; case reports; case-report · DOI 10.5021/ad.2011.23.s3.s314Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI, Hahn NM, Hutson TE, Sonpavde G, Morrissey SC, Buckle GC, Kim WY, Petrylak DP, Ryan CW, Eisenberger MA, Mortazavi A, Bubley GJ, Taplin ME, Rosenberg JE, Kantoff PW.
J Clin Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1200/jco.2011.37.7002Vandetanib for the treatment of thyroid cancer.
Langmuir PB, Yver A.
Clin Pharmacol Ther · review; journal article · DOI 10.1038/clpt.2011.272Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase.
Yu B, Tang LD, Li YL, Song SH, Ji XL, Lin MS, Wu CF.
Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2011.11.061Effects of respiratory mechanical forces on the pharmacological response of lung cancer cells to chemotherapeutic agents.
Hendricks P, Diaz FJ, Schmitt S, Sitta Sittampalam G, Nirmalanandhan VS.
Fundam Clin Pharmacol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1111/j.1472-8206.2011.00964.xImpact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.
Garofalo A, Goossens L, Six P, Lemoine A, Ravez S, Farce A, Depreux P.
Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2011.01.137Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.
Macy ME, DeRyckere D, Gore L.
Invest New Drugs · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1007/s10637-010-9572-6ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.
Yiin JJ, Hu B, Schornack PA, Sengar RS, Liu KW, Feng H, Lieberman FS, Chiou SH, Sarkaria JN, Wiener EC, Ma HI, Cheng SY.
Mol Cancer Ther · research-article; journal article · DOI 10.1158/1535-7163.mct-09-0953The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
Cesca M, Frapolli R, Berndt A, Scarlato V, Richter P, Kosmehl H, D'Incalci M, Ryan AJ, Giavazzi R.
Neoplasia · research support, non-u.s. gov't; research-article; journal article · DOI 10.1593/neo.09866Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy.
Ansiaux R, Dewever J, Grégoire V, Feron O, Jordan BF, Gallez B.
Radiat Res · research support, non-u.s. gov't; journal article · DOI 10.1667/rr1744.1DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study.
Mross K, Fasol U, Frost A, Benkelmann R, Kuhlmann J, Büchert M, Unger C, Blum H, Hennig J, Milenkova TP, Tessier J, Krebs AD, Ryan AJ, Fischer R.
J Angiogenes Res · research-article; journal article · DOI 10.1186/2040-2384-1-5Cutaneous pigmentation after photosensitivity induced by vandetanib therapy.
Kong HH, Fine HA, Stern JB, Turner ML.
Arch Dermatol · research support, n.i.h., intramural; research-article; journal article; case reports · DOI 10.1001/archdermatol.2009.177Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells.
Jane EP, Premkumar DR, Addo-Yobo SO, Pollack IF.
J Pharmacol Exp Ther · comparative study; research-article; journal article; research support, n.i.h., extramural · DOI 10.1124/jpet.109.155705